- Report
- August 2025
- 181 Pages
Global
From €3141EUR$3,545USD£2,717GBP
€3490EUR$3,939USD£3,019GBP
- Report
- August 2025
- 391 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- March 2025
- 150 Pages
Global
From €3411EUR$3,850USD£2,951GBP
€4297EUR$4,850USD£3,718GBP
- Report
- April 2023
- 175 Pages
Global
From €5226EUR$5,899USD£4,522GBP
- Report
- January 2024
- 269 Pages
Global
From €6557EUR$7,660USD£5,481GBP
- Report
- May 2021
- 50 Pages
China
From €2304EUR$2,600USD£1,993GBP
- Report
- July 2021
- 120 Pages
Global
From €4208EUR$4,750USD£3,641GBP
Tazobactam is an antibiotic used in combination with other antibiotics to treat a variety of bacterial infections. It is a beta-lactamase inhibitor, which means it prevents bacteria from breaking down the antibiotics, allowing them to work more effectively. Tazobactam is often used in combination with piperacillin, a broad-spectrum antibiotic, to treat serious infections such as pneumonia, sepsis, and urinary tract infections. It is also used to treat infections caused by multi-drug resistant bacteria.
Tazobactam is available in both injectable and oral forms, and is approved for use in adults and children. It is generally well-tolerated, with few side effects. However, it can cause allergic reactions in some people.
The tazobactam market is a growing segment of the antibiotics market, as it is increasingly used to treat multi-drug resistant infections. It is also used in combination with other antibiotics to treat a variety of bacterial infections.
Some companies in the tazobactam market include Merck, Pfizer, GlaxoSmithKline, and AstraZeneca. Show Less Read more